The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.